{
    "2020-11-16": [
        [
            {
                "time": "",
                "original_text": "医药行业周报：医药子板块表现分化 关注医保谈判进程",
                "features": {
                    "keywords": [
                        "医药",
                        "子板块",
                        "分化",
                        "医保谈判"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：FENLAI TAN减持期届满 累计减持46.1万股 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "FENLAI TAN",
                        "减持",
                        "46.1万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：FENLAI TAN减持0.11%股份，减持计划时间区间届满 拟减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "FENLAI TAN",
                        "减持",
                        "0.11%",
                        "届满"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国产抗肿瘤药获准临床，为境内外均未上市的创新品种",
                "features": {
                    "keywords": [
                        "国产",
                        "抗肿瘤药",
                        "获准临床",
                        "创新品种"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业新药BPI-23314获准临床",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "新药",
                        "BPI-23314",
                        "获准临床"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}